Tango Therapeutics, Inc.
TNGX
शेयरों में रैंक
#4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
शेयर मूल्य
$27.18
अंतिम समन्वयन: 2026-07-31
मार्केट कैप
$3.38B
बदलाव (1 दिन)
-1.41%
बदलाव (1 वर्ष)
202.34%
देश
US
व्यापार Tango Therapeutics, Inc. (TNGX)
श्रेणी
Healthcare
Tango Therapeutics, Inc. (TNGX) के लिए डिविडेंड यील्ड इतिहास
Tango Therapeutics, Inc. (स्टॉक सिंबल: TNGX) की डिविडेंड यील्ड (TTM) 2023-12-31 को: 0.00%
पिछले 5 वर्षों की औसत डिविडेंड यील्ड: 0.00%
पिछले 5 वर्षों की औसत डिविडेंड यील्ड: 0.00%
Tango Therapeutics, Inc. (TNGX) के लिए 2019 से 2026 तक की डिविडेंड यील्ड का इतिहास
प्रत्येक वर्ष के अंत में डिविडेंड यील्ड (TTM)
| वर्ष | डिविडेंड यील्ड | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए डिविडेंड यील्ड (TTM)
| कंपनी | डिविडेंड यील्ड | देश |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
